When looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy. Companies with juicy yields are only worth investing in provided they can support their payouts. We saw just recently that even otherwise solid income stocks with incredible yields can resort to slashing their dividends; that's exactly what happened to Walgreens Boots Alliance and Medical Properties Trust.

Not every high-yield stock will suffer this fate, though. Here is one that likely won't: Pfizer (NYSE: PFE). Though the drugmaker has experienced some issues lately, long-term investors should stick with the stock. Let's find out why.

Pfizer faced an aging portfolio of products and slow revenue growth (at best) before the pandemic. Things only got worse when one of the company's products called Xeljanz, an immunosuppressant, was found to have an increased risk of cardiovascular events and cancer compared to another class of immunology drugs in a post-marketing study in early 2021. The fallout was a boxed warning for Xeljanz.

Continue reading

Source Fool.com